Literature DB >> 18396042

Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt.

Prabhakar A Risbood1, Charles T Kane, Md Tafazzal Hossain, Sudhakarrao Vadapalli, Satish K Chadda.   

Abstract

First synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt is reported.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18396042      PMCID： PMC2430510          DOI： 10.1016/j.bmcl.2008.03.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  2 in total

1.  Syntheses of nucleoside triphosphates.

Authors:  K Burgess; D Cook
Journal:  Chem Rev       Date:  2000-06-14       Impact factor: 60.622

2.  Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

Authors:  S A Veltkamp; M J X Hillebrand; H Rosing; R S Jansen; E R Wickremsinhe; E J Perkins; J H M Schellens; J H Beijnen
Journal:  J Mass Spectrom       Date:  2006-12       Impact factor: 1.982
  2 in total
  5 in total

1.  Triptolide directly inhibits dCTP pyrophosphatase.

Authors:  Timothy W Corson; Hüseyin Cavga; Nicholas Aberle; Craig M Crews
Journal:  Chembiochem       Date:  2011-06-10       Impact factor: 3.164

2.  Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.

Authors:  G S Falchook; M Duvic; D S Hong; J Wheler; A Naing; J Lim; R Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-29       Impact factor: 3.333

3.  Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Christopher Poon; Xiaopin Duan; Christina Chan; Wenbo Han; Wenbin Lin
Journal:  Mol Pharm       Date:  2016-10-21       Impact factor: 4.939

4.  Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.

Authors:  Yuan Zhang; William Y Kim; Leaf Huang
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

5.  SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Authors:  A Khatri; B W Williams; J Fisher; R C Brundage; V J Gurvich; L G Lis; K M Skubitz; A Z Dudek; E W Greeno; R A Kratzke; J K Lamba; M N Kirstein
Journal:  Br J Cancer       Date:  2013-12-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.